| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $322,905 | 6 | 100 |
| TAHL CINDY | See Remarks | 0 | $0 | 3 | $154,764 | $-154,764 |
| Valamehr Bahram | President and CEO | 0 | $0 | 3 | $168,140 | $-168,140 |
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML …
Over the last 12 months, insiders at Fate Therapeutics, Inc. have bought $0 and sold $322,905 worth of Fate Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Fate Therapeutics, Inc. have bought $1.13M and sold $3.89M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 397,964 shares for transaction amount of $668,580 was made by Redmile Group, LLC () on 2024‑12‑20.
| 2026-08-04 | Sale | Valamehr Bahram | President and CEO | 43,947 0.0361% | $2.46 | $108,101 | -7.39% | |
| 2026-08-04 | Sale | TAHL CINDY | See Remarks | 38,800 0.0318% | $2.46 | $95,405 | -7.39% | |
| 2026-05-20 | Sale | Valamehr Bahram | President and CEO | 28,946 0.0254% | $1.88 | $54,482 | +30.98% | |
| 2026-05-20 | Sale | TAHL CINDY | See Remarks | 25,590 0.0224% | $1.88 | $48,084 | +30.98% | |
| 2026-01-09 | Sale | TAHL CINDY | See Remarks | 10,589 0.0093% | $1.06 | $11,275 | +96.19% | |
| 2026-01-09 | Sale | Valamehr Bahram | President and CEO | 5,190 0.0046% | $1.07 | $5,557 | +96.19% | |
| 2025-08-04 | Sale | TAHL CINDY | See Remarks | 9,037 0.0078% | $1.06 | $9,573 | +16.04% | |
| 2025-08-04 | Sale | Valamehr Bahram | President and CEO | 14,466 0.0126% | $1.06 | $15,396 | +16.04% | |
| 2025-01-10 | Sale | Valamehr Bahram | President and CEO | 8,705 0.008% | $1.54 | $13,406 | -23.81% | |
| 2025-01-10 | Sale | TAHL CINDY | See Remarks | 5,654 0.0052% | $1.55 | $8,764 | -23.81% | |
| 2025-01-10 | Sale | Bressi Jerome Charles | See Remarks | 5,980 0.0055% | $1.55 | $9,269 | -23.81% | |
| 2024-12-20 | Sale | Redmile Group, LLC | 341,633 0.2991% | $1.68 | $573,943 | -32.14% | ||
| 2024-12-20 | Redmile Group, LLC | 397,964 0.3484% | $1.68 | $668,580 | -32.14% | |||
| 2024-08-06 | Sale | Xu Yuan | director | 633 0.0005% | $4.23 | $2,678 | -68.30% | |
| 2024-03-04 | Sale | Dulac Edward J III | Chief Financial Officer | 2,447 0.0027% | $7.77 | $19,013 | -51.55% | |
| 2024-01-29 | Sale | Dulac Edward J III | Chief Financial Officer | 1,849 0.0017% | $5.00 | $9,245 | -36.19% | |
| 2024-01-09 | Sale | Wolchko J Scott | President and CEO | 14,391 0.0145% | $4.37 | $62,889 | -14.74% | |
| 2024-01-09 | Sale | Valamehr Bahram | Chief R&D Officer | 11,271 0.0114% | $4.38 | $49,367 | -14.74% | |
| 2024-01-09 | Sale | TAHL CINDY | General Counsel and Secretary | 10,874 0.0109% | $4.37 | $47,519 | -14.74% | |
| 2024-01-09 | Sale | Dulac Edward J III | Chief Financial Officer | 7,028 0.0071% | $4.37 | $30,712 | -14.74% |
| Redmile Group, LLC | 12884277 11.0538% | $26.28M | 9 | 2 | +6.55% | |
| NELSEN ROBERT | 2473188 2.1218% | $5.05M | 1 | 0 | <0.0001% | |
| ARCH VENTURE FUND VI LP | 10 percent owner | 2473188 2.1218% | $5.05M | 1 | 0 | <0.0001% |
| VENROCK ASSOCIATES V LP | 10 percent owner | 2473187 2.1218% | $5.05M | 1 | 0 | <0.0001% |
| Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 2473186 2.1218% | $5.05M | 1 | 0 | <0.0001% |
| RASTETTER WILLIAM H | director | 459272 0.394% | $936,914.88 | 2 | 0 | +1.02% |
| MENDLEIN JOHN | director | 282770 0.2426% | $576,850.80 | 3 | 2 | <0.0001% |
| COUGHLIN TIMOTHY | 57632 0.0494% | $117,569.28 | 1 | 1 | +11.55% | |
| Storgard Chris | Chief Medical Officer | 37593 0.0323% | $76,689.72 | 1 | 0 | +11.55% |
| Nashat Amir | director | 7539 0.0065% | $15,379.56 | 1 | 20 | <0.0001% |
$22,710,871 | 107 | 8.53% | $220.62M | |
$6,146,922 | 96 | -4.70% | $233.68M | |
$60,836,085 | 69 | 0.45% | $255.44M | |
$19,239,249 | 50 | -2.24% | $238.33M | |
$168,352,523 | 35 | 13.58% | $218.79M |
| Increased Positions | 53 | +28.19% | 15M | +20.98% |
| Decreased Positions | 74 | -39.36% | 7M | -9.33% |
| New Positions | 22 | New | 11M | New |
| Sold Out Positions | 21 | Sold Out | 2M | Sold Out |
| Total Postitions | 167 | -11.17% | 81M | +11.65% |
| Redmile Group, Llc | $12,693.00 | 11.19% | 12.87M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $10,531.00 | 9.29% | 10.68M | -129,754 | -1.2% | 2025-09-30 |
| Vanguard Group Inc | $8,675.00 | 7.65% | 8.8M | +31,727 | +0.36% | 2025-09-30 |
| Wilshire Advisors Llc | $8,368.00 | 7.38% | 8.49M | +8M | New | 2025-09-30 |
| Johnson & Johnson | $3,332.00 | 2.94% | 3.38M | 0 | 0% | 2025-09-30 |
| Acadian Asset Management Llc | $2,672.00 | 2.36% | 2.71M | +250,280 | +10.17% | 2025-09-30 |
| Geode Capital Management, Llc | $2,495.00 | 2.2% | 2.53M | +101,045 | +4.16% | 2025-09-30 |
| Vestal Point Capital, Lp | $2,480.00 | 2.19% | 2.52M | 0 | 0% | 2025-09-30 |
| State Street Corp | $2,383.00 | 2.1% | 2.42M | +188,014 | +8.43% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $2,066.00 | 1.82% | 2.09M | -342,754 | -14.06% | 2025-09-30 |